TrialSignal
Clinical trial intelligence report
MRD-guided Treatment With Pembrolizumab and Azacitidine in NPM1mut AML Patients With an Imminent Hematological Relapse
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jul 28, 2026
Report code
NCT03769532-Jul 28, 2026
NCT ID
NCT03769532
Status
TERMINATED
Phase
PHASE2
Sponsor
Technische Universität Dresden
Executive brief
Investment-Ready Snapshot
MRD-guided Treatment With Pembrolizumab and Azacitidine in NPM1mut AML Patients With an Imminent Hematological Relapse is a PHASE2 clinical asset sponsored by Technische Universität Dresden in Acute Myeloid Leukemia. SEO and diligence focus: Pembrolizumab, Azacitidine, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT03769532
Indication
Acute Myeloid Leukemia
Modality
small molecule
Target
Pembrolizumab, Azacitidine
Intervention
Pembrolizumab, Azacitidine
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.